New Pipeline Drugs Offer Hope for Kidney Disease
14 Mar 2012
Sufferers of Polycystic Kidney Disease (PKD) will soon see improvements in the choice of available drug treatments due to the development of therapeutics offering unique new mechanisms of action, according to a new report by pharmaceutical experts GlobalData.
The new report* found that a range of promising drugs are scheduled to launch in the next few years that will better meet patient needs by providing novel functions, offsetting any negative effects upcoming patent expiries will have on the market value.
GlobalData has found that the PKD therapeutics market currently contains significant unmet need due to the absence of approved drug therapies. The currently prescribed drugs, which include antihypertensive medications, are primarily used to alleviate symptoms and delay disease progression, since no disease modifying therapies currently exist. This leads significant unmet need to be present in the market in regards to levels of efficacy, and PKD patients eagerly await superior methods of treatment.
The approval of pipeline products in the near future is likely to address some of the unmet needs in the PKD therapeutics market. Growth in the PKD therapeutics market is primarily attributed to the expected launch of Samsca (tolvaptan) for the treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common type of hereditary cystic kidney disease.
GlobalData’s analysis shows that the PKD developmental pipeline is strong, promising further therapeutic developments. Eight molecules are currently in various stages of clinical development, and the pipeline is filled with novel therapeutic drug classes, including four first-in-class molecules in Phase III. The expected launch of these molecules in the near future is expected to address the current unmet market needs, and propel the market to reach impressive growth rates during the next decade.
In addition, the scheduled patent expiries of Cozaar (US and Europe), Aceon (US), Coreg (US) and Diovan (Europe) are expected to have a minimal impact on the value of the PKD therapeutics market, as the annual cost of therapy associated with these drugs is significantly low.
The PKD therapeutics market was worth $111.4m in 2006, and grew at a Compound Annual Growth Rate (CAGR) of 1.7% to reach $121m in 2011. The market is forecast to grow at a CAGR of 16.1% over the next eight years to reach $400.2m by 2019.
NOTES TO EDITORS
*Polycystic Kidney Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2019
This report is an essential source of information and analysis on the global polycystic kidney disease therapeutics market, identifying key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global polycystic kidney disease therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData is the premier source of actionable insight into the energy and healthcare industries.
With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide
high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase
For further details, please Contact Us.